FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069581036> ?p ?o ?g. }

• W2069581036 endingPage "503" @default.
• W2069581036 startingPage "497" @default.
• W2069581036 abstract "Objective: To calculate the absolute risk reduction of transfusion-related adverse events, the number of patients needed to treat, and cost to avoid one transfusion-related adverse event by using erythropoietin in critically ill patients Design: Number needed to treat with sensitivity analysis. Setting: Teaching hospital. Patients: Hypothetical cohort of critically ill patients who were candidates to receive erythropoietin. Interventions: Using vs. not using erythropoietin to reduce the need for packed red blood cell transfusions. Measurements and Main Results: We used published estimates of known transfusion risks: transfusion-related acute lung injury, transfusion-related errors, hepatitis B and C, human immunodeficiency virus, human T-cell lymphotropic virus, and bacterial contamination, stratified by severity. Based on the estimated risk and frequency of transfusions with and without erythropoietin, we calculated the absolute risk reduction of transfusion-related adverse events, the number needed to treat, and cost to avoid one transfusion-related adverse event by using erythropoietin. The estimated incidence of transfusion-related adverse event was 318 permillion units transfused for all transfusion-related adverse events, 58 per million for serious transfusion-related adverse events, and 21 per million for likely fatal transfusion-related adverse events. The routine use of erythropoietin resulted in an absolute risk reduction of 191 per million for all transfusion-related adverse events, 35 per million for serious transfusion-related adverse events, and 12 per million for likely fatal transfusion-related adverse events. The number needed to treat was 5,246 to avoid one transfusion-related adverse event, 28,785 to avoid a serious transfusion-related adverse event, and 81,000 for a likely fatal transfusion-related adverse event. The total cost was $4,700,000 to avoid one transfusion-related adverse event, $25,600,000 to avoid one serious transfusion-related adverse event, and $71,800,000 to avoid a likely fatal transfusion-related adverse event. The magnitude of these results withstood extensive sensitivity analysis. Conclusions: From the perspective of avoidance of adverse events, erythropoietin does not appear to be an efficient use of limited resources for routine use in critically ill patients." @default.
• W2069581036 created "2016-06-24" @default.
• W2069581036 creator A5010533335 @default.
• W2069581036 creator A5020321122 @default.
• W2069581036 creator A5047784168 @default.
• W2069581036 creator A5082370453 @default.
• W2069581036 creator A5008143843 @default.
• W2069581036 date "2005-03-01" @default.
• W2069581036 modified "2023-09-25" @default.
• W2069581036 title "Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients*" @default.
• W2069581036 cites W127034668 @default.
• W2069581036 cites W1567177660 @default.
• W2069581036 cites W1965148687 @default.
• W2069581036 cites W1970827178 @default.
• W2069581036 cites W1972851153 @default.
• W2069581036 cites W1975270990 @default.
• W2069581036 cites W1978819120 @default.
• W2069581036 cites W1979297402 @default.
• W2069581036 cites W1983258863 @default.
• W2069581036 cites W1984253491 @default.
• W2069581036 cites W1985352910 @default.
• W2069581036 cites W1996634816 @default.
• W2069581036 cites W1998508664 @default.
• W2069581036 cites W2000922018 @default.
• W2069581036 cites W2001614927 @default.
• W2069581036 cites W2004951477 @default.
• W2069581036 cites W2014170536 @default.
• W2069581036 cites W2020433202 @default.
• W2069581036 cites W2021882907 @default.
• W2069581036 cites W2025135310 @default.
• W2069581036 cites W2041005483 @default.
• W2069581036 cites W2057342375 @default.
• W2069581036 cites W2061199175 @default.
• W2069581036 cites W2076488402 @default.
• W2069581036 cites W2091791088 @default.
• W2069581036 cites W2095237614 @default.
• W2069581036 cites W2097517425 @default.
• W2069581036 cites W2107149927 @default.
• W2069581036 cites W2108956977 @default.
• W2069581036 cites W2113782980 @default.
• W2069581036 cites W2120993625 @default.
• W2069581036 cites W2123654848 @default.
• W2069581036 cites W2129549870 @default.
• W2069581036 cites W2142698878 @default.
• W2069581036 cites W2150085168 @default.
• W2069581036 cites W2157449624 @default.
• W2069581036 cites W2162065090 @default.
• W2069581036 cites W2170002664 @default.
• W2069581036 cites W2170812841 @default.
• W2069581036 cites W2322942628 @default.
• W2069581036 cites W2340500438 @default.
• W2069581036 cites W2341616068 @default.
• W2069581036 doi "https://doi.org/10.1097/01.ccm.0000155988.78188.ee" @default.
• W2069581036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15753738" @default.
• W2069581036 hasPublicationYear "2005" @default.
• W2069581036 type Work @default.
• W2069581036 sameAs 2069581036 @default.
• W2069581036 citedByCount "49" @default.
• W2069581036 countsByYear W20695810362012 @default.
• W2069581036 countsByYear W20695810362013 @default.
• W2069581036 countsByYear W20695810362016 @default.
• W2069581036 countsByYear W20695810362017 @default.
• W2069581036 countsByYear W20695810362020 @default.
• W2069581036 countsByYear W20695810362023 @default.
• W2069581036 crossrefType "journal-article" @default.
• W2069581036 hasAuthorship W2069581036A5008143843 @default.
• W2069581036 hasAuthorship W2069581036A5010533335 @default.
• W2069581036 hasAuthorship W2069581036A5020321122 @default.
• W2069581036 hasAuthorship W2069581036A5047784168 @default.
• W2069581036 hasAuthorship W2069581036A5082370453 @default.
• W2069581036 hasConcept C126322002 @default.
• W2069581036 hasConcept C141071460 @default.
• W2069581036 hasConcept C177713679 @default.
• W2069581036 hasConcept C197934379 @default.
• W2069581036 hasConcept C2778534260 @default.
• W2069581036 hasConcept C2780014101 @default.
• W2069581036 hasConcept C71924100 @default.
• W2069581036 hasConceptScore W2069581036C126322002 @default.
• W2069581036 hasConceptScore W2069581036C141071460 @default.
• W2069581036 hasConceptScore W2069581036C177713679 @default.
• W2069581036 hasConceptScore W2069581036C197934379 @default.
• W2069581036 hasConceptScore W2069581036C2778534260 @default.
• W2069581036 hasConceptScore W2069581036C2780014101 @default.
• W2069581036 hasConceptScore W2069581036C71924100 @default.
• W2069581036 hasIssue "3" @default.
• W2069581036 hasLocation W20695810361 @default.
• W2069581036 hasLocation W20695810362 @default.
• W2069581036 hasOpenAccess W2069581036 @default.
• W2069581036 hasPrimaryLocation W20695810361 @default.
• W2069581036 hasRelatedWork W1982482254 @default.
• W2069581036 hasRelatedWork W2012564050 @default.
• W2069581036 hasRelatedWork W2090737987 @default.
• W2069581036 hasRelatedWork W2148240666 @default.
• W2069581036 hasRelatedWork W2512506765 @default.
• W2069581036 hasRelatedWork W2739739656 @default.
• W2069581036 hasRelatedWork W2802036117 @default.
• W2069581036 hasRelatedWork W3049187542 @default.
• W2069581036 hasRelatedWork W4237351857 @default.

• next